This article is more than 5 years old. Information may no longer be current.
VIDEO: Investigational therapy appears non-inferior to classic insulin in treating type 1 diabetes
Click Here to Manage Email Alerts
NEW ORLEANS — The use of MK-1293 – an investigational biosimilar insulin glargine – produced a similar efficacy and safety profile in patients with type 1 diabetes when compared with traditional insulin glargine, Philip D. Home, DM, DPhil, MRCP, of Newcastle University in the United Kingdom, told Endocrine Today.
“The therapeutic profile for MK-1293 could not be distinguished from the classic [insulin glargine],” he said.
In this video, Home discusses the results of a phase 3 trial that demonstrated that MK-1293 (Merck) had a non-inferiority of change from baseline HbA1c at 24 weeks when compared with active insulin glargine (Lantus, Sanofi-Aventis).
“In terms of fasting glucose and self-monitoring glucose, those also did not differ and we went on to look at hypoglycemia, the number of people affected, the event rates, and those did not differ,” he said.
In addition, the two therapies demonstrated similar results in regard to anti-insulin antibody development.